Non-small cell lung cancer

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

AstraZeneca adds another Chinese asset, from Dizal

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

News

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

Nuvalent buy delivers new cancer approval for GSK

AstraZeneca adds another Chinese asset, from Dizal

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Roche's KRAS drug tops its rivals in lung cancer trial

Pfizer's Seagen-derived ADC pipeline suffers a setback

Boehringer advances duo for aggressive cancers into phase 3

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks